How Lung Volume Recruitment Maneuvers Enhance Respiratory Function in Multiple Sclerosis Patients: A Quasi-Randomized Pilot Study.
Claudia EnrichiMartina RegazzettiBłażej CieślikCristiano ZanettiDaniela D'ImperioElisa CompagnoLuisa CaccianteSara FedericoGiorgia PregnolatoMirko ZittiPawel KiperPublished in: Medicina (Kaunas, Lithuania) (2023)
Background and Objectives : In patients with multiple sclerosis (MS), a decrease in muscle strength can lead to limitations in pulmonary functions, potentially causing respiratory complications. To address these challenges, the lung volume recruitment (LVR) maneuver has emerged as a potential intervention. This study sought to evaluate the impact of a four-week LVR protocol on respiratory function in secondary progressive MS patients. Materials and Methods : In a quasi-randomized pre/post-controlled trial, 24 patients with secondary progressive MS were recruited. Participants aged 20-70 years with an EDSS score of 2 to 9 were alternately allocated to intervention ( n = 12) or control groups ( n = 12). The intervention group underwent a 4-week respiratory rehabilitation training focused on LVR, using a standardized cough machine treatment protocol twice daily. The control group received no respiratory intervention. Outcomes measured included forced vital capacity (FVC), maximal insufflation capacity (MIC), and peak cough flow (PCF), using turbine spirometry and other associated equipment. All measurements were taken at baseline (T 0 ) and after 4 weeks (T 1 ) by a blinded assessor. Results : For the intervention group, the mean difference pre/post-treatment in MIC (mL) was 0.45 (SD 1.13) ( p = 0.02), and in MIC (%), it was 0.13 (SD 0.24) ( p = 0.03). Compared to the control group ( n = 10), the between-group mean difference for MIC (mL) was 0.54 ( p = 0.02), and for MIC (%), it was 0.15 ( p = 0.02). Conclusions : The short-term daily LVR protocol notably improved passive lung capacity, despite minimal changes in active lung capacity or cough force. The LVR maneuver offers promise for enhancing respiratory function, especially passive lung capacity, in secondary progressive MS patients. Further research should explore optimal treatment durations and frequencies for more extensive respiratory gains.
Keyphrases
- multiple sclerosis
- randomized controlled trial
- end stage renal disease
- ejection fraction
- mass spectrometry
- newly diagnosed
- ms ms
- prognostic factors
- chronic kidney disease
- double blind
- open label
- placebo controlled
- metabolic syndrome
- blood pressure
- type diabetes
- respiratory tract
- insulin resistance
- risk factors
- phase iii
- risk assessment
- phase ii
- chronic obstructive pulmonary disease
- single molecule
- deep learning
- big data